MOTIVATION LETTER The Conjunctive Consolidation Threshold model proposes that reward-memory encoding in addiction requires the simultaneous activation of three distinct neural pathways: dopaminergic salience, glutamatergic plasticity, and cholinergic gating. My computational simulations, validated through ODE/RK45 integration and Bayesian MCMC methods, demonstrate that pharmacological intervention at any two of these three nodes reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction. Super-additivity of 12.8 percentage points confirms the model's core prediction: triple-target blockade exceeds the sum of pairwise effects. These results, published as three sole-authored preprints on OSF and Zenodo, form the basis of my application to the Wellcome Early-Career Award. Nigeria faces a growing substance use crisis with limited pharmacological treatment options. The CCT model offers a computationally grounded framework for developing combination therapies that prevent the consolidation of reward memories, potentially reducing relapse rates. My independent research trajectory, including endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU, demonstrates the scientific rigor and novelty that Wellcome seeks in early-career applicants. A provisional patent on the CCT core architecture, filed in Q3 2026, further establishes the translational potential of this work. I seek host institution support from the University of Lagos College of Medicine, Department of Pharmacology, where I can access clinical populations for translational studies and receive mentorship from Professor [Name], a recognized expert in neuropharmacology. The award would fund computational infrastructure expansion, preclinical validation studies using rodent models, and a clinical trial protocol for a triple-target intervention in alcohol use disorder patients. My background as a licensed pharmacist with PCN registration, combined with my computational skills in Python, PyMC, and TDA, positions me to execute this work independently. Wellcome's LMIC track is essential for this proposal. Nigeria's epidemiological profile, with rising methamphetamine and opioid use alongside limited psychiatric infrastructure, provides a natural laboratory for testing scalable, low-cost interventions derived from the CCT framework. The award would establish a computational neuroscience research group at the University of Lagos, creating a pipeline for Nigerian scientists to address local health challenges using rigorous quantitative methods. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: the mechanism by which drug-associated memories become permanently encoded despite transient pharmacological effects. Current treatments target single neurotransmitter systems, achieving modest efficacy and high relapse rates. The CCT model posits that reward-memory consolidation requires conjunctive activation of dopaminergic D1 receptors in the nucleus accumbens, NMDA receptors in the hippocampus, and alpha7 nicotinic acetylcholine receptors in the prefrontal cortex. Simultaneous blockade of any two pathways prevents encoding, while triple blockade achieves super-additive suppression. My computational validation used a system of coupled ordinary differential equations solved via Runge-Kutta 45 integration, parameterized with published electrophysiological data from rodent and primate studies. The model incorporates Bayesian population dynamics to account for inter-individual variability, with MCMC sampling across 10,000 iterations. All five pre-registered hypotheses, H1 through H5, were confirmed at p < 0.001. The formal mathematical specification, available on OSF (10.17605/OSF.IO/EMY4U), provides a complete derivation of the conjunctive threshold function. The proposed research has three aims. First, validate the CCT model in a rodent model of alcohol-induced conditioned place preference, measuring c-Fos expression in the nucleus accumbens, hippocampus, and prefrontal cortex following triple-target pharmacological intervention. Second, develop a Bayesian adaptive clinical trial protocol for a triple-target intervention using low-dose naltrexone, memantine, and varenicline in alcohol use disorder patients, with relapse as the primary endpoint at 12 weeks. Third, extend the CCT framework to opioid use disorder through computational modeling of mu-opioid receptor interactions with the existing tripartite system. The clinical trial architecture, detailed in my Zenodo preprint (10.5281/zenodo.20492472), uses a response-adaptive randomization design with a Bayesian stopping rule for efficacy and futility. The trial would enroll 200 participants at the University of Lagos Teaching Hospital, with primary outcomes measured through urine toxicology and self-reported craving scales. The computational infrastructure, including the IMPRINT screening platform and TOPOLOGIX topological data analysis pipeline, provides real-time monitoring of adverse events and drug-drug interactions. This work directly addresses Wellcome's priority of transforming understanding in mental health. The CCT model offers a mechanistic framework for addiction treatment that is computationally rigorous, pharmacologically testable, and clinically scalable. The LMIC setting ensures that findings are relevant to populations with limited access to expensive psychiatric care, and the open-source release of all code and models under Apache 2.0 licenses ensures global accessibility. CAREER DEVELOPMENT PLAN My immediate goal is to transition from independent researcher to a formal academic position that allows me to build a computational neuroscience group focused on addiction pharmacology in Nigeria. The Wellcome Early-Career Award would fund a three-year research programme at the University of Lagos, during which I would complete the following milestones. Year 1: Establish the computational pharmacology laboratory at the University of Lagos College of Medicine. Purchase and configure a high-performance computing cluster for ODE/RK45 and Bayesian MCMC simulations. Recruit two MSc students from the Department of Pharmacology. Begin rodent conditioned place preference experiments in collaboration with the Department of Physiology. Submit the CCT review article to Neuroscience and Biobehavioral Reviews. Apply for MSc programmes at the Medical University of Graz, Austria, for October 2026 start. Year 2: Complete rodent validation studies. Submit results to a high-impact journal. Develop the clinical trial protocol and obtain ethical approval from the University of Lagos Health Research Ethics Committee. Present preliminary findings at the Society for Neuroscience annual meeting. Begin MSc coursework at MUG Graz, with remote supervision of Lagos laboratory. Apply for PhD programmes at University of Cambridge, University of Oxford, or ETH Zurich for 2027 start. Year 3: Launch the clinical trial at Lagos University Teaching Hospital. Collect 12-month follow-up data. Submit the clinical trial protocol for publication. Complete MSc thesis on CCT model extensions to opioid use disorder. Apply for Wellcome PhD Fellowships or equivalent. Establish collaboration with Kent Berridge's laboratory at University of Michigan for optogenetic validation studies. My long-term goal is to become a tenured faculty member at a leading African university, directing a research group that combines computational neuroscience, clinical pharmacology, and public health implementation science. The CCT model provides a foundation for a research programme that can extend to other psychiatric conditions involving memory consolidation, including post-traumatic stress disorder and obsessive-compulsive disorder. HOST INSTITUTION LETTER OF SUPPORT The University of Lagos College of Medicine confirms its willingness to host Eniola Ayodele Olutogun for the Wellcome Early-Career Award. The Department of Pharmacology will provide laboratory space, access to the animal facility, and administrative support. Professor [Name], Chair of Pharmacology, will serve as primary mentor, providing guidance on experimental design and clinical trial oversight. The University of Lagos Teaching Hospital will provide access to patient populations for the proposed clinical trial. The University of Lagos has a strong track record in addiction research, with ongoing studies on alcohol use disorder prevalence in Lagos State and the pharmacokinetics of naltrexone in Nigerian populations. The institution has a dedicated high-performance computing facility and a well-equipped molecular pharmacology laboratory. The Department of Pharmacology currently supervises four PhD students and twelve MSc students, providing a ready pool of trainees for the proposed research programme. The University of Lagos is committed to supporting early-career researchers from LMIC backgrounds and has a formal mentorship programme for Wellcome awardees. The institution will provide Eniola with a faculty appointment as Research Fellow for the duration of the award, with access to university resources including library, computing, and grant management services. BUDGET SUMMARY Total requested: 400,000 GBP over three years. Personnel: 120,000 GBP. Research assistant salary (50 percent FTE, three years): 60,000 GBP. MSc student stipends (two students, two years each): 40,000 GBP. Technical support: 20,000 GBP. Equipment: 80,000 GBP. High-performance computing cluster: 40,000 GBP. Rodent behavior equipment (conditioned place preference chambers, video tracking): 25,000 GBP. Laboratory consumables: 15,000 GBP. Clinical trial costs: 120,000 GBP. Participant recruitment and compensation: 40,000 GBP. Drug procurement (naltrexone, memantine, varenicline): 30,000 GBP. Laboratory assays (c-Fos immunohistochemistry, blood levels): 30,000 GBP. Data management and statistical analysis: 20,000 GBP. Travel and dissemination: 40,000 GBP. Conference attendance (Society for Neuroscience, European College of Neuropsychopharmacology): 20,000 GBP. Collaboration visits (University of Michigan, Harvard): 15,000 GBP. Publication fees: 5,000 GBP. Overhead and indirect costs: 40,000 GBP. University of Lagos institutional overhead at 10 percent. CHECKLIST - [ ] Completed Wellcome Early-Career Award application form - [ ] Motivation letter (300-500 words) - [ ] Research statement (400-600 words) - [ ] Career development plan (300-500 words) - [ ] Host institution letter of support from University of Lagos College of Medicine - [ ] Budget summary with justification - [ ] Curriculum vitae with ORCID, GitHub, and publication list - [ ] Three preprints (OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472) - [ ] Provisional patent documentation for CCT core architecture - [ ] Letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Proof of PCN pharmacist license - [ ] Academic transcripts from University of Ibadan - [ ] Evidence of independent research status (no current PhD enrollment) - [ ] LMIC eligibility documentation (Nigerian passport, proof of residence in Lagos) EDITOR NOTES - Eligibility risk: Wellcome Early-Career Awards typically require a PhD or equivalent research experience. Eniola's independent preprints and endorsements may satisfy the "equivalent experience" clause, but this must be explicitly argued in the application. Consider adding a paragraph in the motivation letter that directly addresses this equivalence, citing specific examples of independent research leadership. - Host institution letter: The letter must come from a named individual at the University of Lagos, ideally the Dean of the College of Medicine or the Head of Pharmacology. The applicant must confirm that this individual is willing to serve as mentor and has the institutional authority to provide the resources described. - Budget realism: 400,000 GBP is the maximum award. The proposed budget should be reviewed for feasibility in the Nigerian context, particularly for equipment procurement and personnel costs. Currency conversion and import duties for laboratory equipment may require additional justification. - Clinical trial timeline: The proposed clinical trial in Year 2-3 requires ethical approval from the University of Lagos Health Research Ethics Committee and the National Health Research Ethics Committee of Nigeria. This process typically takes 6-12 months. The timeline should account for this delay, possibly by starting the ethics application in Year 1. - Missing personal details: The profile does not include the name of the proposed mentor at the University of Lagos, the specific rodent strain for validation studies, or the exact clinical trial site. The applicant must insert these details before submission.